Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy, with advantages over traditional protein inhibition. Despite significant advancements in novel degraders such as bivalents and multitargeting proteolysis-targeting chimeras (PROTACs), key challenges persist in the development pipeline, particularly regarding the identification of highly potent degraders and the optimization of their drug-like properties. Here, we reported a multimodal modular assembled targeting chimera (multi-MOATAC) strategy that enabled intracellular click chemistry-mediated in situ assembly of ligand modules with targets, integrating multiple functional units into binary/ternary complexes. This strategy validated significantly enhanced degradation efficiency via trivalent self-assembling degraders and identified a highly effective self-assembly stoichiometric ratio, achieving a DC 50 of 4.6 ± 1.3 nM for BRD4 in MDA-MB-231 cells. To evaluate broad applicability, the target scope was expanded from nuclear protein BRD4 to challenging targets, including membrane-localized EGFR and cytoplasmic protein ALK. Furthermore, optimizing the stoichiometric ratio of self-assembling modules achieved parallel degradation of distinct targets. The superior antitumor efficacy of trivalent self-assembling PROTACs was also confirmed in vivo . The highly modular and scalable multi-MOATAC strategy may enable broad applications in developing novel tissue-specific degraders and advancing therapeutics for related diseases.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: